Abstract : This study aimed to evaluate the frequency, distribution, and corresponding histology of MUC1 expression in colorectal cancer and examine its association with clinicopathological factors. MUC1 expression was con rmed in 86 of 169 surgically resected colorectal cancers 51% , although the ratio of MUC1-positive cells was less than 5% in 33 cases 20% , 5-50% in 46 cases 27% , and greater than 50% in only 7 cases 4% . None or less than 5% of MUC1 expression cases were classi ed as L-group cancers 116 cases, 69% , while cancers showing higher than 5% expression were classi ed into the H-group 53 cases, 31% . Analysis of the intratumoral distribution of positive cells in the H-group cases showed MUC1 expression distributed predominantly in the upper layers in 3 cases 6% , in the lower layers in 18 cases 34% , and in all layers in 32 cases 60% . MUC1 expression was observed in various histomorphological cancer forms, but the most frequent expression was noted in the monolayer cuboidal pancreatobiliary-type neoplastic glands. Considering the relationship between MUC1 expression and clinicopathological factors, H-group cases demonstrated signi cantly larger lesions showing a greater number of ulcerated-type cancers, deeper invasion, poorer differentiation, higher frequency of budding, and higher rate of lymph node metastasis than L-group cancers. Furthermore, there was a difference of 10% between the H-group and L-group with regard to the frequency of relapse/tumor mortality three years after surgery. In colorectal cancer, MUC1 expression increases with progression of the tumor indicating that it is one of the useful indicators of malignancy and may facilitate appropriate treatment regimens ; however, as its expression is heterogeneous and localized, it will be necessary to con rm the state of MUC1 expression by case.
Introduction
Up to the early 1990s, there was an increase in the rate of colorectal cancer in Japan that coincided with the westernization of eating habits and increased prevalence of overweight and obese individuals Thereafter, the rate began to level off and presently, approximately 105,000 people are diagnosed with colorectal cancer every year. In recent years, advancements in medical care and diagnostic technologies have resultsed in colorectal cancers being detected at an early stage, and improved surgical or endoscopic resection has increased the number of cases with complete cure. However, the number of deaths still exceeds 40,000 people each year 1 .
In accordance with the progression of colorectal cancers, chemotherapy is frequently used as an adjuvant treatment or as part of multidisciplinary therapy 2 . Although the effectiveness of chemotherapy has improved over the years, results remain unsatisfactory 3 . Further improving the cure rates of cancer chemotherapy will require that the treatment regimen and drugs used to be carefully selected according to the speci c traits of tumor cells, such as their sensitivity to speci c anticancer drugs and the presence of tumor-associated antigens.
This importance of personalized treatment will also be considered in the treatment of colorectal cancer, because some colorectal cancers show a heterogeneous cell lineage and partially or predominantly lack the characteristics of an intestinal-type cancer.
MUC1 is a mucin antigen highly expressed in pancreatobiliary-type cancer, such as ductal adenocarcinoma of the pancreas or bile duct, and is a marker of heterogeneity in colorectal cancer. We recently decided to investigate MUC1 expression in colorectal cancer because it is a marker for poor prognosis 4 , its expression may affect the selection of chemotherapeutic agents and use of MUC1-cytotoxic T-lymphocyte CTL immunotherapy 5 , and little is reported about MUC1 expression in colorectal cancer tissues to date 6 7 .
This study investigated the frequency and distribution of MUC1 expression in colorectal cancer with respect to the corresponding histology, and examined the association of these ndings with the patient s pathological prognostic factors.
Materials and Methods

Objectives
The Two types of positive reactions were observed in the tumor cells. The rst was a thick, outer-layer staining of the tumor cell membranes, while the second was a light, occasionally dense, diffuse, granular staining of the cytoplasm. As the latter positive reaction was observed in the normal epithelium, only the former positive reaction was considered signicant for MUC1 detection.
Clinicopathological examination
We rst examined the frequency and distribution of MUC1 expression in the cancer tissue, and then compared these with MUC1 expression in lymph node metastatic lesions from the study patients, 59 pancreatic cancers, and 10 small intestinal cancers. Next, histomorphological features showing MUC1 expression were evaluated. Finally, the relationship between MUC1 expression and clinicopathological factors, especially those related to unfavorable prognosis, was investigated. For statistical analysis, chi-square tests and Student s t-tests were used, and a P-value 0.05 was considered signi cant.
Results
Frequency and distribution
MUC1 expression was con rmed in 86 cases 51% ; however, the proportion of MUC1-positive cells was 0% in 83 of the tumor samples 49% , 1-5% in 33 cases 20% , 5-50% in 46 cases 27% , and greater than 50% in only 7 cases 4% . Hence, the negative and extremely low 5% MUC1-expressing cases hereafter known as the MUC1 L-group comprised approximately 70% of the total number of cases 1 . MUC1 expression in common intestinal-type tubular adenocarcinomas was also noticed, although it was infrequent.
MUC1 expression and clinicopathological factors
We compared the clinicopathological factors in 53 cases 31% of the MUC1 H-group with those in 116 cases 69% of the MUC1 L-group Table 5 . No signi cant difference was observed in age, gender, or tumor localization between the groups ; however, the MUC1 H-group exhibited signi cantly greater tumor size than the MUC1 L-group 5.2 cm vs. 4.0 cm diameter, respectively , more ulcerated-type tumors 91% vs. 76%, respectively , deeper in ltration depth for T2 and T3 cancer cases 98% vs. 83%, respectively , lower differentiation state moderately to poorly differentiated : 74% vs. 57%, respectively , greater frequency of budding 58% vs. 41%, respectively , and higher rate of lymph node metastasis 43% vs. 21%, respectively . These ndings indicated a strong correlation between MUC1 expression and malignancy factors. Furthermore, a difference of 10% in the frequency of relapse/tumor mortality between the H-group 35% and the L-group 25% was observed three years after surgery. In an examination of only T3 cancer cases, several factors failed to show statistically significant differences, but there remained a significant difference in lymph node metastasis between the H-group 47% and the L-group 27% Table 6 .
Adjuvant chemotherapy was administered almost equally to patients in both groups, namely 26 cases in the MUC1 H-group 51%, 2 cases unknown and 48 cases in the MUC1 L-group 42%, 3 cases unknown .
Discussion
The histological structure of colorectal cancers is fairly uniform, with the majority showing intestinal-type tubular adenocarcinomas with high expression of the intestinal markers CDX2 9 and MUC2 10 . On the other hand, the MUC1 examined in this study is con- expression has been reported at various frequencies 32-50% 4 12 in colorectal cancer 13 .
The reasons for the difference in positivity rates may include differences in the MUC1 antibody used, the signi cant positive reactions graded, and in standards for classifying positive cases. In considering all levels of MUC1 expression, our study found MUC1 expression in approximately half of the cases. However, only 4% of these 7 of 169 cases showed a MUC1-positive cell ratio of greater than 50%. This result was in contrast with 70% 41 of 59 cases of pancreatic cancers which exhibited MUC1 positivity at a ratio of greater than 50% in additional studies. Thus, unlike for pancreatobiliary cancers, MUC1 expression in colorectal cancer can only be considered a secondary trait.
However, even if MUC1 expression in colorectal cancer is a minor phenomenon, its expression should not be overlooked. In this study, MUC1 expression was clearly observed in 53 cases classi ed into the MUC1 H-group, of which all except one were either T2 or T3 advanced cancer cases. Therefore, the frequency of MUC1 expression tended to be higher with the stage of the tumor, consistent with a previous study 14 . Furthermore, the MUC1-positive cells were mostly throughout all layers or predominantly in the lower layers, both of which included the invasive fronts. This distribution pattern has been already noted by
Baldus et al 15 and Hiraga et al 16 , who reported MUC1 expression as an independent factor indicative of unfavorable prognosis. Moreover, we con rmed that the majority of tumors in the MUC1-H group exhibited high levels of continuous MUC1 expression in lymph node metastatic lesions, and that even in the MUC1-L group, 38% showed high levels of MUC1 expression.
This study also aimed to clarify the relationship between MUC1 expression and clinicopathological factors. To date, MUC1 is known to be a signi cant marker of unfavorable prognosis in colorectal cancer 4 . In this study, we found that the MUC1 H-group exhibited a signi cantly greater tumor size, greater number of ulcerated-type tumors, deeper in ltration depth, lower states of differentiation, greater frequency of budding, and higher rate of lymph node metastasis than the MUC1 L-group. These ndings indicate a strong correlation between MUC1 expression and malignant factors Table 5 . In an examination of only T3 cancer cases, although the number of cases was small and several factors lacked statistical signi cance, the MUC1 H-group samples tended to show a stronger relationship with malignant factors than samples from the MUC1 L-group, as well as a signi cant difference in lymph node metastases 17 Table 5 . Thus, these results indicate that MUC1 expression in colorectal cancer is related to malignancy 18 , affects localized progression of the cancer and its metastasis, and is useful as a tumor marker and treatment target 19 20 .
Finally, MUC1 expression was found in various histological features of colorectal cancer, making it impossible to identify speci c morphological features of the tumor tissues that favor MUC1 expression. However, the ndings of frequent MUC1 expression in the monolayer cuboidal pancreatobiliary-type neoplastic glands, which were often transformed from intestinal type glands, was considered important and a subject for future study.
Conclusion
In colorectal cancer, MUC1 expression increases with development of the tumor, and exhibits a strong correlation with malignant factors. Thus, MUC1 is a useful malignant marker and an indicator for treatment regimen. However, its expression is heterogeneous and localized ; therefore, it will be necessary to con rm the state of MUC1 expression with tissues including the invasive front or metastasis on a case-by-case basis.
